Nkarta (NKTX) Profit After Tax (2019 - 2026)
Nkarta (NKTX) posted quarterly Profit After Tax of -$27.8 million for Q1 2026, up 13.04% year-over-year from -$24.6 million in Q1 2025, and down 1.54% quarter-over-quarter from -$27.4 million in Q4 2025.
Nkarta (NKTX) Profit After Tax (2019 - 2026) Analysis & Trends
Nkarta's Profit After Tax history runs 8 years deep, the most recent figure standing at -$27.8 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 13.04% year-over-year to -$27.8 million; the TTM figure through Mar 2026 stood at -$99.9 million (up 10.19% YoY), while the FY2025 annual figure was -$104.1 million, up 4.33% from the prior year.
- Profit After Tax for Q1 2026 stood at -$27.8 million, down from -$27.4 million in the prior quarter.
- The five-year high for Profit After Tax was -$21.7 million in Q3 2025, with the low at -$33.3 million in Q2 2023.
- The 5-year median for Profit After Tax is -$27.8 million (2026), against an average of -$27.8 million.
- The sharpest annual moves came in 2022 and 2024: Profit After Tax plunged 79719.44% in 2022, then gained 24.92% in 2024.
- Nkarta's Profit After Tax stood at -$31.9 million in 2022, then increased by 12.26% to -$28.0 million in 2023, then rose by 7.45% to -$25.9 million in 2024, then retreated by 5.68% to -$27.4 million in 2025, then dropped by 1.54% to -$27.8 million in 2026.
- Business Quant data shows NKTX's Profit After Tax at -$27.8 million in Q1 2026, -$27.4 million in Q4 2025, and -$21.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | -40.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40.66 Mn |
| Mar 31, 2026 | -27.83 Mn |
| Dec 31, 2025 | -27.41 Mn |
| Sep 30, 2025 | -21.72 Mn |
| Jun 30, 2025 | -22.98 Mn |
| Mar 31, 2025 | -32.01 Mn |
| Dec 31, 2024 | -25.94 Mn |
| Sep 30, 2024 | -28.34 Mn |
| Jun 30, 2024 | -24.99 Mn |
| Mar 31, 2024 | -29.52 Mn |
| Dec 31, 2023 | -28.02 Mn |
| Sep 30, 2023 | -25.65 Mn |
| Jun 30, 2023 | -33.29 Mn |
| Mar 31, 2023 | -30.82 Mn |
| Dec 31, 2022 | -31.94 Mn |
| Sep 30, 2022 | -28.74 Mn |
| Jun 30, 2022 | -26.92 Mn |
| Mar 31, 2022 | -25.99 Mn |
| Dec 31, 2021 | -22.97 Mn |
| Sep 30, 2021 | -36,000.00 |